002286.SHE Baolingbao Biology Co Ltd
- Market cap
- CNY 2.87B
- P/E
- 19.8x
- P/B
- 1.23x
- ROE
- 6.5%
- Dividend yield
- 1.11%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 002286.SHE undervalued?
Graham number002286.SHE trades 4.0% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Baolingbao Biology Co Ltd fundamental analysis
No fundamental analysis for Baolingbao Biology Co Ltd yet.
Baolingbao Biology Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Baolingbao Biology Co Ltd
Baolingbao Biology Co.,Ltd., together with its subsidiaries, engages in the research, development, manufacturing, and sale of functional sugar in China and internationally. The company offers prebiotics, including galacto-oligosaccharides, isomaltooligosaccharides, fructooligosaccharides, and xylooligosaccharides; sugar alcohols and sources, such as erythritol, trehalose, crystallized fructose, allulose, and maltotetrasaccharide; dietary fiber comprising polydextrose and res…
Full company profileBaolingbao Biology Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Baolingbao Biology Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.38B | 1.59B | 1.73B | 1.81B | 2.05B | 2.76B | 2.71B | 2.52B | 2.40B | 2.75B | 3.01B |
| Gross Profit | 202M | 213M | 241M | 267M | 187M | 368M | 308M | 198M | 278M | 365M | 425M |
| Operating Income | 49.7M | 57.9M | 54.1M | 46.3M | 60.7M | 236M | 160M | 64.0M | 154M | 189M | 206M |
| EBITDA | 142M | 142M | 166M | 176M | 169M | 359M | 286M | 207M | 263M | 307M | 191M |
| Net Income | 49.3M | 49.6M | 43.0M | 35.2M | 49.9M | 202M | 133M | 54.0M | 111M | 151M | 152M |
| EPS | 0.13 | 0.13 | 0.12 | 0.10 | 0.14 | 0.54 | 0.36 | 0.15 | 0.30 | 0.40 | 0.40 |
| Balance Sheet | |||||||||||
| Total Assets | 1.93B | 2.11B | 2.58B | 2.52B | 2.62B | 3.03B | 3.01B | 2.66B | 2.67B | 2.78B | 3.01B |
| Total Liabilities | 423M | 582M | 1.04B | 952M | 1.02B | 1.22B | 1.00B | 675M | 632M | 548M | 679M |
| Shareholders' Equity | 1.51B | 1.52B | 1.54B | 1.57B | 1.60B | 1.81B | 2.00B | 1.98B | 2.04B | 2.23B | 2.33B |
| Cash & Short-term Investments | 263M | 231M | 416M | 416M | 485M | 692M | 376M | 243M | 255M | 274M | 295M |
| Total Debt | 137M | 260M | 499M | 490M | 235M | 401M | 506M | 248M | 261M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 109M | -36.9M | 133M | 154M | 398M | 206M | 30.8M | 282M | 249M | 259M | - |
| Capital Expenditure | 96.5M | 99.0M | 174M | 95.5M | 132M | 92.8M | 255M | 152M | 190M | 189M | 241M |
| Free Cash Flow | 12.5M | -136M | -40.7M | 58.5M | 267M | 113M | -224M | 130M | 58.8M | 70.1M | 46.4M |
| Ratios | |||||||||||
| ROE | 3.3% | 3.3% | 2.8% | 2.2% | 3.1% | 11.1% | 6.6% | 2.7% | 5.4% | 6.7% | 6.5% |
| ROA | 2.6% | 2.4% | 1.7% | 1.4% | 1.9% | 6.7% | 4.4% | 2.0% | 4.2% | 5.4% | 5.0% |
| Net Profit Margin | 3.6% | 3.1% | 2.5% | 2.0% | 2.4% | 7.3% | 4.9% | 2.1% | 4.6% | 5.5% | 5.1% |
| Debt to Equity | 0.09x | 0.17x | 0.32x | 0.31x | 0.15x | 0.22x | 0.25x | 0.13x | 0.13x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Baolingbao Biology Co Ltd dividends
- Dividend yield
- 1.11%
- Forward dividend
- 0.15 CNY
- Payout ratio
- 21.2%
- Ex-dividend date
- Oct 14, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 31.9M | 0.08 | 21.2% |
| 2024 | CNY 55.3M | 0.15 | 49.8% |
| 2023 | CNY 49.8M | 0.14 | 92.2% |
| 2022 | CNY 22.3M | 0.06 | 16.8% |
| 2021 | CNY 22.2M | 0.06 | 11.0% |
| 2020 | CNY 11.1M | 0.03 | 22.2% |
| 2019 | CNY 11.1M | 0.03 | 31.4% |
| 2018 | CNY 61.2M | 0.17 | 142.5% |
| 2017 | CNY 36.8M | 0.10 | 74.1% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 20:10 on Jun 9, 2014.
Who owns Baolingbao Biology Co Ltd
- Insiders 34.86%
- Institutions 5.77%
- Public & others 59.37%
- Shares outstanding 380M
- Free float 240M
Baolingbao Biology Co Ltd company profile
- Company name
- Baolingbao Biology Co Ltd
- Ticker
- 002286.SHE
- ISIN
- CNE100000FL1
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Aug 28, 2009
- Sector
- Healthcare
- Industry
- Food Products
- Employees
- 1,505
- Fiscal year end
- December
- Address
- No. 1, East Outer Ring Road, Yucheng, China, 251200
- Phone
- 86 53 4891 8612
- Website
- blb-cn.com
About Baolingbao Biology Co Ltd
Baolingbao Biology Co.,Ltd., together with its subsidiaries, engages in the research, development, manufacturing, and sale of functional sugar in China and internationally. The company offers prebiotics, including galacto-oligosaccharides, isomaltooligosaccharides, fructooligosaccharides, and xylooligosaccharides; sugar alcohols and sources, such as erythritol, trehalose, crystallized fructose, allulose, and maltotetrasaccharide; dietary fiber comprising polydextrose and resistant dextrin; modified, waxy corn, and corn starch products; starch sugar, which includes maltodextrose, high fructose syrup, solid corn syrup, maltodextrin, and glucose syrup; and animal nutrition products, such as baolekang and fubaokang. It also provides health plans comprising low sugar and calorie; nutritional fortification; microecological regulation; exclusive customization; texture optimization; medical aesthetics and daily chemical products; and antibiotic-reduced farming. The company's products are used in dairy products, drinks, snack food, health products and dietary supplements, candy, special dietary food, chemicals, and animal nutrition applications. It exports its products. The company was founded in 1997 and is based in Yucheng, China.
Baolingbao Biology Co Ltd management
5- Mr. Zhou YuFinancial Director & CFO · born 1978
- Ms. Xia LiDeputy General Manager · born 1976
- Mr. Feng LiuExecutive Deputy GM, Board Secretary & Non-Independent Director · born 1973
- Mr. Qiang WangChairman & GM · born 1962
- Wen Xiu WenAccounting Supervisor